Efficacy and safety of fluvastatin 80 mg or valsartan 160 mg and their combination in dyslipidemic patients with arterial hypertension and endothelial dysfunction
Phase of Trial: Phase IV
Latest Information Update: 19 Oct 2015
At a glance
- Drugs Fluvastatin; Valsartan
- Indications Dyslipidaemias; Hypertension
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Novartis
- 07 Nov 2011 Actual end date (September 2005) added as reported by ClinicalTrials.gov.
- 30 Oct 2005 New trial record.